Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cisplatin doublets with hypofractionated radiotherapy for locally advanced non-small cell lung cancer
NL-OMON56676Phase 2Withdrawn
- Sponsor
- Netherlands Cancer Institute
- Start
- Nov 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of cisplatin, pemetrexed and etoposide in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Netherlands Cancer Institute. Primary endpoint: Rate of grade 5 treatment-related adverse events. Planned start Nov 2016; status: withdrawn.
02
Drugs
cisplatinpemetrexedetoposide
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON56676.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56676.